Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study
First-line pembrolizumab monotherapy demonstrated moderate efficacy and acceptable safety in patients with advanced NSCLC with PD-L1 TPS of 1% to 49%. Liver metastasis, high NLR, and poor performance status were identified as prognostic factors.
Authors
- Kinnosuke Matsumoto (ORCID: https://orcid.org/0000-0002-4930-6997)
- Satoshi Tanaka (ORCID: https://orcid.org/0000-0002-1057-2585)
- Osamu Morimura
- Kouji Azuma
- Akihiro Tsukaguchi (ORCID: https://orcid.org/0009-0009-6296-4386)
- Toshie Niki
- Akito Miyazaki (ORCID: https://orcid.org/0009-0004-7188-674X)
- Kensuke Kanaoka (ORCID: https://orcid.org/0000-0002-1266-7043)
- Kiyohide Komuta
- Yuhei Kinehara
- Yasuhiro Mihashi
- Masahide Mori (ORCID: https://orcid.org/0009-0007-9223-3854)
- Midori Yoneda
- Keijiro Yamauchi
- Koki Moritomo
- Akihiro Tamiya
- Yoshito Takeda
- Motohiro Tamiya
- Takayuki Shiroyama
- Hidekazu Suzuki
- Atsushi Kumanogoh
- Tomoki Kuge
- Akio Osa
Institutions
- Japan Agency for Medical Research and Development (JP)
- Osaka Prefectural Medical Center (JP)
- Osaka City University (JP)
- Toyonaka Municipal Hospital (JP)
- Osaka National Hospital (JP)
- Nishinomiya Municipal Central Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Toneyama National Hospital (JP)
- Kinki Central Hospital (JP)
- National Hospital Organization (JP)
- Osaka International Cancer Institute (JP)
- Nippon Medical School Hospital (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Osaka International University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1016/j.jtocrr.2026.100953
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00